(Q38985771)

8 September 2017

1 reference

title

Circulating tumor cells in breast cancer: applications in personalized medicine (English)

1 reference

8 September 2017

main subject

personalized medicine

1 reference

Jin Sun Lee

1

1 reference

8 September 2017

Mark Jesus M Magbanua

series ordinal

2

1 reference

8 September 2017

John W Park

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

19 October 2016

1 reference

Breast Cancer Research and Treatment

8 September 2017

published in

1 reference

8 September 2017

volume

160

1 reference

8 September 2017

issue

3

1 reference

8 September 2017

page(s)

411-424

1 reference

Targeted Therapies in Breast Cancer: New Approaches and Old Challenges

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Detection, clinical relevance and specific biological properties of disseminating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Clinical significance of circulating tumor cells in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumour cells in non-metastatic breast cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Advances in genomic characterization of circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cell analysis in metastatic triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Microfluidic, marker-free isolation of circulating tumor cells from blood samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Meta-analysis of the prognostic value of circulating tumor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Method validation of circulating tumour cell enumeration at low cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Expression profiling of circulating tumor cells in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Quantitative high-resolution genomic analysis of single cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Molecular biomarker analyses using circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Global gene expression profiling of circulating tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Biomarkers characterization of circulating tumour cells in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Cytokeratin-based CTC counting unrelated to clinical follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Imaging cytometry for counting circulating tumor cells: comparative analysis of the CellSearch vs ImageStream systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

In vitro detection of circulating tumor cells compared by the CytoTrack and CellSearch methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Statistical considerations for enumeration of circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4014-6

10.1007/S10549-016-4014-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1039047357

0 references

1 reference